

Update from NRS Reproductive Health and Childbirth Specialty Group

September 2022

Autumn in Johnston Gardens, Aberdeen



CHIEF
SCIENTIST
OFFICE

Invitation from The Chief Scientist Office (CSO):

The CSO is hosting a virtual information event about the National Institute for Health and Care Research (NIHR) funding programmes available to Scottish-led Researchers

Time: 24 October 2022, 10:00 – 12:30. Location: MS Teams.

The CSO operates within the wider landscape of UK health research funding and contributes to a NIHR total funding pool in excess of £100m annually. This allows researchers based in Scotland to apply for the majority of the research programmes administered by NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC).

The purpose of this event is to raise awareness among the research community in Scotland and to provide information on the remit of the NIHR panels and the application process with the aim to increasing the number and quality of Scottish-led proposals.

The event will include presentations from NIHR as well as researchers with experience of successful NETSCC funding proposals. A more detailed agenda will follow.

Please follow the link [here](#) to register for the event. The event is free and open to anyone who is interested. We therefore ask you to circulate/publicise this within your organisation and to those you believe would benefit from attending.

If you have any questions regarding the event, please contact Louise Campbell (Louise.Campbell@gov.scot) or Alan McNair (Alan.McNair@gov.scot)

Reminder: SHARE Autumn Symposium 'Tomorrow's Medical World'

Wednesday 28th September 2022, 1 - 3pm

Following the success of SHARE's inaugural symposium in January 2022, the SHARE team is proud to present the second online symposium of the series:



We are delighted to introduce Professor Dame Anna F Dominiczak, Chief Scientist Scotland (Health) as our keynote speaker. The event will be chaired by Professor Iain B McInnes CBE, Vice-Principal and Head of College of Medical, Veterinary and Life Sciences, University of Glasgow.

Our Programme highlights five guest speakers who will share their experiences in the field of research. For further details please visit this link:

<https://www.registerforshare.org/news/share-autumn-symposium-wed-28th-sept-1-3pm>.

A Certificate of Attendance will be issued; this may be used towards any CPD points.

Please send us your good news stories, queries, etc:

Abha (abha.maheshwari@abdn.ac.uk), NRS Clinical Research Lead, or
Txaro (maria.amezaga@nhs.scot), NRS Champion Support Manager

NEW STUDY IN SET- UP IN SCOTLAND

CRAFT: CeRclarge After Full dilatation caesarean secTion; an investigation into the role of previous in labour caesarean section in future preterm birth risk and potential management strategies.

CPMS ID 42833, IRAS 261294. CI: Professor Andrew Shennan, St Thomas' Hospital, London

Worldwide, there is a 9.6% rate of preterm birth before 37 weeks. The timing of delivery is directly related to infant risk. Extremely preterm deliveries under 28 weeks' gestation carry greater risk for lung development, cerebral palsy, eye problems, as well as long-term difficulties and costs.

Risk factors increasing a woman's risk of preterm birth include surgery to the neck of the womb, previous preterm birth and multiple pregnancy. A newly identified factor is previous caesarean delivery in the later stages of labour (particularly when fully dilated). We don't know how significant this is, but it seems to increase the risk of preterm birth under 28 weeks, and late miscarriages (after 14 weeks pregnant). Because this is a recently recognised risk factor, we need to learn more, and how to reduce the risks.

There will be three components to the CRAFT project: 1) CRAFT-OBS: Observational study of women with a previous term caesarean in labour; 2) OBS Control group: to compare the rate of preterm birth in the OBS cohort to women with only previous term vaginal delivery/(ies); 3) CRAFT-IMG Study: Imaging sub-study to characterise any scars found, this will only take place at University College London Hospital and St Thomas' Hospital.

For further details please contact the CRAFT Study team at: craftstudy@kcl.ac.uk

In Scotland, NHS Grampian is interested in participating.



KING'S
College
LONDON

COMMERCIAL STUDY IN SET-UP PENDING APPROVAL IN ENGLAND AND IN SCOTLAND

OASIS 4. Overall Assessment of efficacy and Safety of elinzanetant In patients with vasomotor Symptoms in women with, or at high risk for developing hormone-receptor positive breast cancer. A double-blind, randomized, placebo-controlled multicentre study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms caused by adjuvant endocrine therapy, over 52 weeks in women with, or at high risk for developing hormone-receptor positive breast cancer.

CPMS ID 49518, IRAS 1006034. CI: Dr Paula Briggs, Liverpool Women's Foundation Trust.

Funder: Bayer Consumer Care AG.

In Scotland, NHS Grampian and NHS Greater Glasgow & Clyde are on board.

